J Invest Dermatol:雄激素受体介导的旁分泌信号诱导雄激素性脱发毛乳头血管退行性变

2022-01-21 医路坦克 MedSci原创

雄激素性脱发(AGA),本研究表明,在毛囊小型化的早期,DP细胞的AR介导的旁分泌信号(主要是转化生长因子-β信号)诱导了DP内血管的退化,并支持了早期抗雄激素治疗优于晚期抗雄激素治疗的观点。

      雄激素性脱发(AGA),或男性型秃顶,是一种常见的雄激素依赖型脱发障碍,在男性和女性中都会发生。它的特点是粗的末端毛发逐渐地、有图案地转变成细的绒毛(称为毛囊小型化),最终导致秃顶。所有毛囊(HFs)在一生中反复经历生长(生长期)、退化期(退化期)、休止期(休止期)的周期。在AGA中,毛囊的小型化发生在毛囊周期中,伴随着生长期的缩短和休止期的延长。这导致静息HFs的百分比增加,产生微观毛发(确定是这个名词?)。毛囊周期依赖于HF干细胞(HfSCs)的活动,hfSCs主要由HFs底部的信号中心真皮乳头(DP)控制。在人类头皮毛囊中,穿透DP的血管被认为是负责向DP提供营养以支持HFs生长的Journal预先防御。然而,在毛囊生物学领域,尤其是在毛发疾病方面,尚未见有关DP中血管行为的报道。

     虽然AGA的分子发病机制仍不清楚,但双氢睾酮(DHT)和雄激素受体信号通路被认为是AGA发生所必需的。以前的研究表明,具有II5型α还原酶基因缺陷的男性不会秃顶。II5DHT还原酶是一种将睾酮转化为二羟色胺的酶。目前公认的治疗AGA的方法包括非那雄胺、米诺地尔和毛发移植。非那雄胺(一种选择性的II5型α还原酶抑制剂)的治疗作用进一步证实了双羟色胺及其受体AR在AGA发病机制中的重要作用。全基因组关联研究(GW AS)也揭示了雄激素受体基因(AR)及其邻近的胞外营养不良蛋白A2受体基因(EDA2R)是AGA的主要基因座。尽管已有证据表明雄激素和雄激素受体信号通路在AGA发生发展中的重要性,但AR在AGA毛囊中的具体定位仍存在争议,AR参与AGA发病的下游机制仍很不明确。

     在本研究中,我们显示AR患者的头皮秃顶真皮乳头(DP)中AR的核定位升高。考虑到AR在DP中的特定定位和AR的重要性,我们对AGA患者额叶和非额叶枕头皮的DP进行了完整的转录组测序,以研究AGA的发病机理。结果显示,与AGA患者的非秃顶头皮相比,秃顶头皮DP中的微血管异常。我们进一步证实,在AGA发育的毛囊小型化的起始阶段,秃顶头皮的DP中血管消失了。巧合的是,我们发现在小鼠中,随着生长期的开始,微血管在DP周围增加,并且血管生成对于毛发再生是必需的。在机制上,我们证明了旁分泌信号传导,主要是TGF-β信号传导,来自受AR调节的DP细胞的Journal Pre-proof促进了AGA发育中秃顶头皮DP中微血管内皮细胞的凋亡。

    综上所述,本研究表明,在毛囊小型化的早期,DP细胞的AR介导的旁分泌信号(主要是转化生长因子-β信号)诱导了DP内血管的退化,并支持了早期抗雄激素治疗优于晚期抗雄激素治疗的观点。

文献来源:Deng Z,  Chen M,  Liu F,Androgen receptor-mediated paracrine signaling induces regression of blood vessels in the dermal papilla in androgenetic alopecia.J Invest Dermatol 2022 Jan 13;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682714, encodeId=83af1682e144c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 19 06:33:16 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051750, encodeId=b0012051e5073, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 30 14:33:16 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350591, encodeId=e40013505910f, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629922, encodeId=58a51629922b0, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-12-19 gwc392
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682714, encodeId=83af1682e144c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 19 06:33:16 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051750, encodeId=b0012051e5073, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 30 14:33:16 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350591, encodeId=e40013505910f, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629922, encodeId=58a51629922b0, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682714, encodeId=83af1682e144c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 19 06:33:16 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051750, encodeId=b0012051e5073, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 30 14:33:16 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350591, encodeId=e40013505910f, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629922, encodeId=58a51629922b0, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682714, encodeId=83af1682e144c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 19 06:33:16 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051750, encodeId=b0012051e5073, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 30 14:33:16 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350591, encodeId=e40013505910f, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629922, encodeId=58a51629922b0, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Sat Jan 22 13:33:16 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 lfcmxl

相关资讯

热门推荐!《脱发的临床诊疗新进展》

梅斯公开课为皮肤科医生提供大量免费临床诊疗课程!

直播回放:脱发的临床诊疗新进展

脱发的临床诊疗新进展-冉玉平(四川大学华西医院)

JAAD:雄激素性脱发的毛囊周围炎症和毛囊海绵样变

雄激素性脱发通常被归类为非炎性,非瘢痕性脱发,该研究中大多数病例小型化卵泡附近有炎症。几个高度小型化的卵泡也被严重的炎症包围。峡部偏爱和炎症与小型化卵泡的关联潜在地暗示了一种可能的机制关系。

JEADV:小剂量口服米诺地尔增加雄激素性脱发患者头发密度和厚度

虽然外用米诺地尔一直是雄激素性脱发(AGA)的主要治疗方法,但口服米诺地尔直到最近才被研究。LDOM是一种耐受性良好的治疗方法,与其他药物联合使用时密度增加.

JAAD:变性人群雄激素性脱发如何治疗?

雄激素性脱发(AGA)是变性和性别多样性(TGD)患者面临的重大临床和治疗挑战。尽管性别确认激素疗法影响头发生长,但很少有关于TGD人群中AGA的研究。

JAAD:雄激素性脱发真的是非炎症性脱发吗?

雄激素性脱发(AGA)可能影响多达50%的成年人。虽然AGA被归类为非炎症性、非瘢痕性脱发,但炎症的组织学证据早已得到认可。本文进一步研究了雄激素性脱发的炎症性反应。